Comparative Pharmacology
Head-to-head clinical analysis: THYREL TRH versus XYLOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYREL TRH versus XYLOSE.
THYREL TRH vs XYLOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic thyrotropin-releasing hormone (TRH) that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
Xylose is a pentose sugar that is absorbed in the small intestine via passive diffusion and active transport. It is used to assess intestinal mucosal integrity; its absorption reflects the function of the enterocytes. After absorption, it is not metabolized and is excreted unchanged in urine, making it a marker for intestinal absorption and renal function.
Adult: 500 mcg IV bolus over 15-30 seconds; may repeat once after 15-30 minutes if needed.
Adults: 25 g orally in 500 mL water, administered as a single dose for D-xylose absorption test.
None Documented
None Documented
Terminal elimination half-life is approximately 5–6 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation and renal clearance, requiring rapid intravenous administration for diagnostic thyroid stimulation.
Terminal elimination half-life: 1.2-2.5 hours in adults with normal renal function; prolonged in renal impairment (up to 10 hours).
Primarily renal excretion of intact TRH and metabolites (deamido-TRH and acid-TRH). Approximately 90% of administered radioactivity is recovered in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Renal: approximately 85-90% eliminated unchanged in urine; biliary/fecal: negligible (<5%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent